CUROSURF^® (poractant alfa)
Health Economics and Value Team

Discover the potential clinical and economic outcomes of using CUROSURF

The CUROSURF Value Model

The interactive CUROSURF Value Model customizes inputs for your institution and outlines potential clinical outcomes and cost implications of using standard surfactant administration versus early rescue surfactant administration.

CUROSURF Value Model goals¹

Demonstrate potential cost implications of standard surfactant administration versus early rescue surfactant administration as it relates to clinical outcomes

Provide key information for US healthcare decision-makers like quality personnel, pharmacy administration, and P&T Committee members

Support payors or formulary committees in drug selection for coverage or reimbursement

CUROSURF Value Model inputs & outputs

Content in this section is intended specifically for US population health decision makers who support the care of premature infants with RDS.

Click to Reveal

The CUROSURF Value Model uses clinical assumptions based on available data on patient characteristics, dosing, safety, utilization, and costs to calculate meaningful clinical and economic outputs.

The outputs in this model are subject to assumptions and methodology described within the model and the data the user selects or decides to input in the model. Calculations are based solely on infants with RDS who are intended to undergo surfactant or ventilation interventions.

Graphic showing the CUROSURF customer values, evidence-based impacts, and other considerations. Customer values include impacts of surfactant timing and administration strategies, practice standardization, and clinical decisions relative to total cost. Evidence-based impacts include redosing, days on mechanical ventilation, cost avoidance and incidence of complication rates, and total cost of care. Other considerations include NICU quality initiatives, bronchopulmonary dysplasia committee support, and standardization of care.

*Exogenous surfactants are not indicated for the prevention of BPD.

CUROSURF was assumed to be used in all treatment strategies. This model is considered health economics and value information. It is important to note that overall economic impact is dependent on specific patient populations, institutional practices, and local cost structures.

BPD=bronchopulmonary dysplasia; FiO₂=fraction of inspired oxygen; NICU=neonatal intensive care unit; P&T=Pharmacy and Therapeutics; RDS=respiratory distress syndrome.

Explore the CUROSURF Value Model with a Health Economics and Value Specialist.

Get in Touch

This information can be provided to a payor, formulary committee, or other similar entity with knowledge and expertise in the area of the health economics analysis, carrying out its responsibilities for the selection of drugs for coverage or reimbursement.

Learn more about CUROSURF & the Value Model

Access information about CUROSURF clinical profile, pharmacology, and dosing

Visit CUROSURF.com

Connect with a Health Economics and Value Specialist today to learn more about the CUROSURF Value Model

Important Safety Information

CUROSURF^® (poractant alfa) is intended for intratracheal use only. The administration of exogenous surfactants, including CUROSURF, can rapidly affect oxygenation and lung compliance. Therefore, infants receiving CUROSURF should receive frequent clinical and laboratory assessments so that oxygen and ventilatory support can be modified to respond to respiratory changes.

CUROSURF should only be administered by those trained and experienced in the care, resuscitation, and stabilization of preterm infants.

Transient adverse reactions associated with administration of CUROSURF include bradycardia, hypotension, endotracheal tube blockage, and oxygen desaturation. These events require stopping CUROSURF administration and taking appropriate measures to alleviate the condition. After the patient is stable, dosing may proceed with appropriate monitoring.

Pulmonary hemorrhage, a known complication of premature birth and very low birth-weight, has been reported with CUROSURF. The rates of common complications of prematurity observed in a multicenter single-dose study that enrolled infants 700–2000 g birth weight with RDS requiring mechanical ventilation and FiO₂ ≥ 0.60 are as follows for CUROSURF 2.5 mL/kg (200 mg/kg) (n=78) and control (n=66; no surfactant) respectively: acquired pneumonia (17% vs. 21%), acquired septicemia (14% vs. 18%), bronchopulmonary dysplasia (18% vs. 22%), intracranial hemorrhage (51% vs. 64%), patent ductus arteriosus (60% vs. 48%), pneumothorax (21% vs. 36%) and pulmonary interstitial emphysema (21% vs. 38%).

Indication

CUROSURF^® (poractant alfa) Intratracheal Suspension is indicated for the rescue treatment of Respiratory Distress Syndrome (RDS) in premature infants. CUROSURF reduces mortality and pneumothoraces associated with RDS.

Please see Full Prescribing Information.

Reference: 1. Data on file. Chiesi USA, Inc.

CUROSURF® (poractant alfa)Health Economics and Value Team